Cervical Cancer Treatment Market Research Report - Forecast to 2027

Cervical Cancer Treatment Market Information: By Type (Squamous Cell Carcinomas, Adenocarcinomas, Adenosquamous Carcinomas), Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy), End-User (Cancer Care Centers) - Forecast Till 2027

ID: MRFR/Pharma/4378-HCR | February 2023 | Region: Global | 100 Pages         

Cervical Cancer Treatment Market Speak to Analyst Request a Free Sample

Cervical Cancer Treatment Market

Cervical Cancer Treatment market is expected at a CAGR of 6.5% to hit USD 9.9 Billion during the forecast 2030

Segmentation
By Type Squamous Cell Carcinomas Adenocarcinomas Adenosquamous Carcinomas
By Treatment Surgery Radiation Therapy Chemotherapy Targeted Therapy
By End-User Cancer Care Centers
Key Players
Companies Profiled   Pfizer Inc.   GlaxoSmithKline   Bristol-Myers Squibb Company   ALLERGAN   Actavis Pharma Company   Eli Lilly and Company   Alnylam Pharmaceuticals Inc   Hetero   Biocon   Novartis   Genentech USA
Drivers
Market Driving Forces   Increasing prevalence of cervical cancer   Increasing awareness about cervical cancer among women
Request a Free Sample

Cervical Cancer Treatment Market Overview Global Cervical Cancer Treatment market is expected to grow at a CAGR of 6.5% during the forecast period. The bottom section of the uterus that attaches to the vagina is known as the cervix. Cervical cancer begins in the cervix's cells. Most cervical cancers are caused by strains of the Human Papillomavirus (HPV), a sexually transmitted infection. The disease starts when healthy cells get mutated, resulting in uncontrolled cell growth. These cells produce a tumor that spreads throughout the surrounding tissues. Cervical malignancies are classified as squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas. Squamous cell carcinomas arise from ectocervical cells, whereas adenocarcinomas arise from gland cells. Under the microscope, the cancer cells are thought to resemble squamous cells. Squamous cell carcinomas and adenocarcinomas coexist in adenosquamous carcinomas. Cervical cancer treatment options include cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy. Cervical cancer is diagnosed via cystoscopy, proctoscopy, anesthetic, and imaging investigations such as computed tomography (CT), magnetic resonance imaging (MRI), intravenous urography, and Positron Emission Tomography (PET scan). The rising prevalence of cervical cancer and raising awareness of cervical cancer among women are driving the cervical cancer therapy market. Moreover, the growing need for early detection and treatment of cervical cancer is likely to propel the cervical cancer treatment Market forward throughout the forecast period. The high expense of therapy, on the other hand, is fueling the expansion of the cervical cancer treatment industry.

FIGURE 1: Global Cervical Cancer Treatment Market, by Region, 2016 (%)


 Cervical Cancer Treatment Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentatio Recent Development

Cancer, according to the World Health Organization (WHO), was the top cause of death worldwide in 2015, accounting for 8.8 million fatalities. The market for cervical cancer diagnostics and therapies is fragmented, competitive, and dominated by a few significant competitors.


Few big firms, such as Pfizer Inc., now dominate the market in terms of market share. Companies are currently concentrating their efforts on creating new diagnostic procedures, such as liquid-based cytology.


Cancer, according to the World Health Organization (WHO), was the top cause of death worldwide in 2015, accounting for 8.8 million fatalities. The market for cervical cancer diagnostics and therapies is fragmented, competitive, and dominated by a few significant competitors.


Few big firms, such as Pfizer Inc., now dominate the market in terms of market share. Companies are currently concentrating their efforts on creating new diagnostic procedures, such as liquid-based cytology.


Intended Audience



  • Healthcare Software Companies

  • Clinical Software Vendors

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology:


 cervical cancer treatment Method


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Segments 


The global cervical cancer treatment market is segmented on the basis of type, treatment, and end-user.


On the basis of type, the cervical cancer treatment market is segmented into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas.


On the basis of treatment, the cervical cancer treatment market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others.


Surgery is further segmented into cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, trachelectomy, and others.


Radiation Therapy is further segmented into external beam radiation and brachytherapy


Chemotherapy is further segmented into cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab, and others.


Targeted therapy is further segmented into bevacizumab and pazopanib.


Hormone therapy is further segmented into oestrogen, progesterone, progestogens, and testosterone.


On the basis of end-user, the cervical cancer treatment market is segmented into cancer care centers, diagnostic centers, pharmacies, and others.


Regional Analysis of the Cervical Cancer Treatment Market  


Globally, Americas is the largest market for cervical cancer treatment whose growth is attributed to technological advancements in the field of oncology, increasing prevalence of cervical cancer, and development of new imaging devices by key players in the market. In North America, the market is driven by the increasing awareness of causes and risk factors of cervical cancer and its treatment. In the U.S., the market is driven by the increasing importance of women healthcare and changing lifestyle of women. South America exhibits a steady growth in the cervical cancer treatment market.


In the European countries, the growth of the cervical cancer treatment market is attributed to a number of healthcare institutions offering treatment of cancer and huge investments in research and development activities by the U.K. and Germany. In Germany, the market is mainly driven by an increase in the use of new technological devices for the diagnosis and treatment of cancer.


In Asia Pacific, the cervical cancer treatment market exhibits numerous growth opportunities due to rising awareness about cervical cancer and the increasing demand for cost-effective treatment solutions such as chemotherapy. Japan, China, and India are the largest contributors to the market growth where the market is driven by the increasing emphasis on cancer detection and treatment and the rising prevalence of cancer. Additionally, availability of skilled healthcare professionals in research also accelerates the growth of the cervical cancer treatment market. The increasing government support of oncology research and women healthcare initiatives and the rapid growth of the healthcare imaging industry in India and China fuel the f=growth of the market in the regions.


In the Middle East, Saudi Arabia and the United Arab Emirates (U.A.E.) are the largest contributors to the market growth due to the focus on the development of new healthcare facilities catering to the needs of cancer patients and availability of technologically advanced diagnostic devices of management. In African countries, the increasing number of healthcare initiatives for women health and improvement in healthcare infrastructure are likely to boost the growth of the cervical cancer treatment market.


Key Players in the Global Cervical Cancer Treatment Market   


Some of the key players in this cervical cancer treatment market are Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Hetero, Biocon, Novartis, Genentech USA, and others.



Report Scope:

Report Attribute/Metric Details
  Market Size    2027: Significant Value
  CAGR   6.5% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Hetero, Biocon, Novartis, Genentech USA, and others
  Key Market Opportunities   Increasing demand for early diagnosis and treatment of cervical cancer
  Key Market Drivers

  • Increasing prevalence of cervical cancer
  • Increasing awareness about cervical cancer among women


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Cervical Cancer Treatment Market is projected to grow at a 6.5% CAGR between 2020-2027.

    The Americas is expected to lead the Cervical Cancer Treatment Market.

    Rising prevalence of cervical cancer is boosting market growth.

    Key players in the Cervical Cancer Treatment Market include Genentech USA, Novartis, Biocon, Hetero, Alnylam Pharmaceuticals, Inc, Eli Lilly and Company, Actavis Pharma Company, ALLERGAN, Bristol-Myers Squibb Company, GlaxoSmithKline, and Pfizer Inc.